XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at multiple sites. Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established in collaboration with the scientific advisory committee of the European Medicines Agency (EMA).
Dr. Tamas Hickish, lead investigator of the European program, said, “I believe this study of a completely novel drug will give new insight into how to treat advanced bowel cancer. The innovative approach to target IL-1a is a fascinating concept in the treatment of advanced cancer. The strong enrollment is a reflection of the need for anti-cancer therapies that maintain patient health while treating the disease.”
The Company’s Xilonix therapeutic monoclonal antibody targets the molecular signaling known to stimulate growth of blood vessels and breakdown of connective tissue. The same signals may be involved in metastasis and messaging to the brain to cause pain, fatigue, anxiety, appetite suppression and hypermetabolic syndrome seen in advanced cancer. Earlier observations of Xilonix therapy in advanced cancer patients suggested physical recovery that strongly correlated with significant improvement in survival in colorectal cancer (Hong et al. Lancet Oncology 2014). These findings formed the basis for developing this unique regulatory pathway in Europe in collaboration with the EMA.
The Phase III trial is evaluating the efficacy of Xilonix in patients with metastatic colorectal cancer that is refractory to standard therapy. The trial design is double-blind, placebo-controlled and randomizes patients (2:1) to Xilonix plus best supportive care (BSC), or to placebo plus BSC. Eligible patients have metastatic colorectal cancer, have progressed on an oxaliplatin- and irinotecan-based regimen and are experiencing symptoms due to their underlying malignancy. The co-primary endpoint of improvement in lean body mass and improvement in quality of life is assessed after eight weeks of therapy, using whole body DEXA scanning for body composition assessment and the validated EORTC QLQ-C30 questionnaire for life quality assessment. The co-primary endpoints were designed to capture important surrogates for anti-cancer treatment effect, especially those that have been found in the past to correlate independently with improved overall survival. After completing assessment of the primary endpoint at eight weeks, patients are eligible to cross over into an open label extension of Xilonix.
Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech’s True Human antibodies are cloned directly from individual donors who possess natural immunity against certain diseases. For more information on the ongoing trial in the United States, visit www.XCITE.com.
Copyright © 2015 CancerConnect. All Rights Reserved.